Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atreca, Inc. of its common stock for up to an aggregate amount of $100 million.
Atreca is a…
Davis Polk advised the underwriters in connection with an initial public offering of 9,315,000 shares of common stock of Berkeley Lights, Inc. at $22.00 per share (which includes the…
Davis Polk advised the representatives of the several underwriters in connection with a $125 million SEC-registered common stock offering by Atreca, Inc. The common stock is listed on…
Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…
Davis Polk advised the initial purchaser in connection with a Rule 144A offering by CryoLife, Inc. of $100 million aggregate principal amount of its 4.250% convertible senior notes due 2025…
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 5,980,000 shares of common stock of ChemoCentryx, Inc. (which…
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Alector, Inc. of shares of its common stock for up to a maximum offering price of …
Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by NeoGenomics, Inc. of 4,400,000 shares of its common stock and $175 million…
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Coherus BioSciences, Inc. of $200 million aggregate principal amount of its…
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Natera, Inc. of $287.5 million aggregate principal amount of its 2.25%…